Ucb Biopharma Srl

This study tests the long-term safety and effectiveness of zilucoplan, a daily injection, in people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. About 200 participants who completed a prior zilucoplan trial will receive the drug for an extend…

This study is checking the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). It involves 760 participants who have already completed earlier studies of the drug. Researchers will monitor side effects over time to see if th…

This study tests a drug called rozanolixizumab in 12 children aged 2 to 18 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug is safe and helps control symptoms. Participants receive injections, and resea…

This study tests an investigational drug called rozanolixizumab in adults with MOG antibody-associated disease (MOGAD), a rare condition where the immune system attacks the brain and spinal cord. The main goal is to see if the drug can prevent or delay relapses (flare-ups) compar…

This study tests a drug called certolizumab pegol (Cimzia) in children aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see how the drug moves through the body and whether it is safe. Some children will get the drug, others a placebo. The study is active but …

This phase 3 trial is testing the long-term safety of bimekizumab, a drug that targets inflammation, in 658 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful boils. Participants who completed a previous study will receive bimek…

This study tests whether bimekizumab works better than risankizumab for adults with active psoriatic arthritis (PsA), a condition causing joint pain and skin lesions. About 684 participants will receive one of the two drugs for 16 weeks. The main goal is to see who gets at least …

This program provides brivaracetam (Briviact) to epilepsy patients who were already taking it in earlier studies, bridging the gap until the drug is commercially available. Patients continue their individual doses, up to 200 mg per day, with adjustments based on seizure control a…

This program provides ongoing access to certolizumab pegol (Cimzia) for adults with rheumatoid arthritis who took part in earlier open-label studies. Participants receive the standard maintenance dose of 200 mg every two weeks. The goal is to allow continued disease management or…

This study is testing the long-term safety and effectiveness of bimekizumab, a drug that reduces inflammation, in 508 adults with active axial spondyloarthritis (including ankylosing spondylitis). Participants who completed earlier trials will receive the drug for an extended per…

This study tests the drug bimekizumab in 89 adults with moderate to severe plaque psoriasis, some of whom also have psoriatic arthritis. Researchers will measure changes in gene activity in skin samples after 48 weeks of treatment. The goal is to understand how the drug affects t…

This study looks at the long-term safety of a daily injection called zilucoplan in children with a rare muscle-weakening disease called generalized myasthenia gravis. It includes up to 8 children who have already completed a previous study. The goal is to see if the drug remains …

This study looks at the long-term safety of a drug called rozanolixizumab in children aged 2 and older with generalized myasthenia gravis, a condition that causes muscle weakness. The drug is given in 6-week treatment cycles. The main goal is to track serious side effects and see…

This study tests whether brivaracetam, taken as an oral solution, can stop absence seizures in people aged 2 to 25 with childhood or juvenile absence epilepsy. Participants receive either the drug or a placebo, and seizure freedom is checked using a 24-hour EEG after 14 days. The…

This study tests the long-term safety of an inhaled medication called Staccato alprazolam for people aged 12 and older who have prolonged seizures. About 300 participants will use the inhaler when a seizure starts to see if it stops the seizure quickly and without serious side ef…